GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Equity-to-Asset

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Equity-to-Asset : 0.96 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Great Novel Therapeutics Biotech & Medicals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$618.04 Mil. Great Novel Therapeutics Biotech & Medicals's Total Assets for the quarter that ended in Dec. 2023 was NT$644.85 Mil. Therefore, Great Novel Therapeutics Biotech & Medicals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.96.

The historical rank and industry rank for Great Novel Therapeutics Biotech & Medicals's Equity-to-Asset or its related term are showing as below:

ROCO:7427' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.78   Med: 0.95   Max: 0.97
Current: 0.96

During the past 6 years, the highest Equity to Asset Ratio of Great Novel Therapeutics Biotech & Medicals was 0.97. The lowest was 0.78. And the median was 0.95.

ROCO:7427's Equity-to-Asset is ranked better than
96.21% of 1557 companies
in the Biotechnology industry
Industry Median: 0.67 vs ROCO:7427: 0.96

Great Novel Therapeutics Biotech & Medicals Equity-to-Asset Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Equity-to-Asset Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.78 0.96 0.91 0.97 0.96

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.91 0.87 0.97 0.93 0.96

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's Equity-to-Asset

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Great Novel Therapeutics Biotech & Medicals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Equity-to-Asset falls into.



Great Novel Therapeutics Biotech & Medicals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Great Novel Therapeutics Biotech & Medicals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=618.036/644.849
=0.96

Great Novel Therapeutics Biotech & Medicals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=618.036/644.849
=0.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Great Novel Therapeutics Biotech & Medicals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines